avapro has been researched along with Vascular Diseases in 1 studies
Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.
irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.
Vascular Diseases: Pathological processes involving any of the BLOOD VESSELS in the cardiac or peripheral circulation. They include diseases of ARTERIES; VEINS; and rest of the vasculature system in the body.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yusuf, S | 1 |
| Healey, JS | 1 |
| Pogue, J | 1 |
| Chrolavicius, S | 1 |
| Flather, M | 1 |
| Hart, RG | 1 |
| Hohnloser, SH | 1 |
| Joyner, CD | 1 |
| Pfeffer, MA | 1 |
| Connolly, SJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Parallel Randomized Controlled Evaluation of Clopidogrel Plus Aspirin, With Factorial Evaluation of Irbesartan, for the Prevention of Vascular Events, in Patients With Atrial Fibrillation[NCT00249795] | Phase 3 | 9,016 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The considered event is the death over the duration of the follow-up whatever the cause, cardiovascular or non-cardiovascular. (NCT00249795)
Timeframe: Median follow-up of 4.5 years
| Intervention | participants (Number) |
|---|---|
| Irbesartan | 949 |
| Placebo | 929 |
The considered event is the first overnight hospital stay for HF over the duration of the follow-up, after validation by the EAC. (NCT00249795)
Timeframe: Median follow-up of 4.5 years
| Intervention | participants (Number) |
|---|---|
| Irbesartan | 482 |
| Placebo | 551 |
The considered event is the overnight hospital stay for any CV cause other than Heart Failure over the duration of follow-up, as reported by the investigator (i.e. not validated by the Event Adjudication Committee). (NCT00249795)
Timeframe: Median follow-up of 4.5 years
| Intervention | participants (Number) |
|---|---|
| Irbesartan | 1186 |
| Placebo | 1174 |
The considered event is the first occurence of any HF episode defined as evidence of signs and symptoms of HF with or without hospitalization over the duration of follow-up, as reported by the investigator (i.e. not validated by the Event Adjudication Committee). (NCT00249795)
Timeframe: Median follow-up of 4.5 years
| Intervention | participants (Number) |
|---|---|
| Irbesartan | 699 |
| Placebo | 767 |
The considered event is the first occurrence of stroke (nonfatal or fatal, ischemic, hemorrhagic or of uncertain type) over the duration of follow-up, after validation by the EAC. (NCT00249795)
Timeframe: Median follow-up of 4.5 years
| Intervention | participants (Number) |
|---|---|
| Irbesartan | 379 |
| Placebo | 411 |
The first co-primary event is the first occurence of any component of the following cluster over the duration of follow-up: myocardial infarction (nonfatal or fatal), stroke (nonfatal or fatal) or vascular death - after validation by the Event Adjudication Committee (EAC). (NCT00249795)
Timeframe: Median follow-up of 4.5 years
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| All components | - Myocardial Infarction (fatal or not) | - Stroke (fatal or not) | - Vascular death | |
| Irbesartan | 963 | 136 | 367 | 460 |
| Placebo | 963 | 123 | 407 | 433 |
The second co-primary event is the first occurence of any component of the following cluster over the duration of follow-up: myocardial infarction (nonfatal or fatal), stroke (nonfatal or fatal), vascular death or hospitalization for heart failure - after validation by the EAC. (NCT00249795)
Timeframe: Median follow-up of 4.5 years
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| All components | - Myocardial Infarction (fatal or not) | - Stroke (fatal or not) | - Vascular death | - Hospitalization for heart failure | |
| Irbesartan | 1236 | 122 | 340 | 331 | 443 |
| Placebo | 1291 | 112 | 375 | 291 | 513 |
1 trial available for avapro and Vascular Diseases
| Article | Year |
|---|---|
Irbesartan in patients with atrial fibrillation.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Biphenyl Compounds; Blood Pressu | 2011 |